Search
01/01/2023
CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome
Al-Hakem H., Doets A.Y., Stino A.M., Zivkovic S.A., Andersen H., Willison H.J., Cornblath D.R., Gorson K.C., Islam Z., Mohammad Q.D., Sindrup Sø.H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J.A.L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S.E., Arends S., Luijten L.W.G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G.A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R.P., Marchesoni C., Tous M.J.S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F.H., Waheed W., Lehmann H.C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F.A., Visser L.H., Katzberg H.D., Dardiotis E., Attarian S., Van Der Kooi A.J., Eftimov F., Wirtz P.W., Samijn J.P.A., Jacobus Gilhuis H., Hadden R.D.M., Holt J.K.L., Sheikh K.A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T.E., Faber C., Kramers H., Busby M., Roberts R.C., Silvestri N.J., Fazio R., Van Dijk G.W., Garssen M.P.J., Verschuuren J., Harbo T., Jacobs B.C.. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. NEUROLOGY. 2023; 100(23)DOI:10.1212/WNL.0000000000207282. PMID:37076309. IF:8.400(Q1/1D).
01/01/2023
Rituximab treatment in myasthenia gravis
Vesperinas-Castro A., Cortés-Vicente E.. Rituximab treatment in myasthenia gravis. Frontiers in Neurology. 2023; 14DOI:10.3389/fneur.2023.1275533. PMID:37849836. IF:2.700(Q2/4D).
01/01/2023
Colorimetric fusion of attenuation and birefringence in OCT signatures: a screening tool for evaluating muscular degradation in alpha-sarcoglican deficit murine models
Mieites V., Pardo A., Gutiérrez-Gutiérrez J.A., Suárez-Calvet X., López-Higuera J.M., Díaz-Manera J., Conde O.M.. Colorimetric fusion of attenuation and birefringence in OCT signatures: a screening tool for evaluating muscular degradation in alpha-sarcoglican deficit murine models. Proceedings of SPIE. 2023; 12632DOI:10.1117/12.2670555. PMID:. IF:(Q/D).
01/01/2023
Wide-field optical properties estimation of whole limbs in muscle dystrophy murine models via SFDI: A case study
Mieites V., Gutíerrez-Gutíerrez J.A., Pardo A., Súarez-Calvet X., Lopez-Higuera J.M., Diaz-Manera J., Conde O.M.. Wide-field optical properties estimation of whole limbs in muscle dystrophy murine models via SFDI: A case study. Proceedings of SPIE. 2023; 12627DOI:10.1117/12.2670573. PMID:. IF:(Q/D).
01/01/2023
Falls Predict Acute Hospitalization in Parkinson's Disease.
Santos García D, de Deus Fonticoba T, Cores C, Castro ES, Hernández Vara J, Jesús S, Mir P, Cosgaya M, Martí MJ, Pastor P, Cabo I, Seijo M, Legarda I, Vives B, Caballol N, Rúiz Martínez J, Croitoru I, Cubo E, Miranda J, Alonso Losada MG, Labandeira C, López Ariztegui N, Morales-Casado M, González Aramburu I, Infante J, Escalante S, Bernardo N, Blázquez Estrada M, Menéndez González M, Caldentey JG, Borrué C, Vela L, Catalán MJ, Gómez Mayordomo V, Kurtis M, Prieto C, Ordás C, Nogueira V, López Manzanares L, Ávila Rivera MA, Puente V, García Moreno JM, Solano Vila B, Álvarez Sauco M, Carrillo Padilla F, Carlos Martínez Castrillo J, Sánchez Alonso P, Gastón I, Kulisevsky J, Valero C, de Fábregues O, González Ardura J, López Díaz LM, Martinez-Martin P. Falls Predict Acute Hospitalization in Parkinson's Disease.. Journal of Parkinsons Disease. 2023; 13(1)DOI:10.3233/JPD-212539. PMID:33843696. IF:4.000(Q2/3D).
01/01/2023
Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients
Gironell A., Pascual-Sedano B., Marín-Lahoz J., Pérez J., Pagonabarraga J.. Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients. Movement Disorders Clinical Practice. 2023; 10(1)DOI:10.1002/mdc3.13576. PMID:36704076. IF:2.600(Q2/5D).